Antibody-directed enzyme prodrug therapy: Efficacy and mechanism of action in colorectal carcinoma

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 765-772

  Napier, M P ^a   Sharma, S K ^a   Springer, C J ^b   Bagshawe, K D ^a   Green, A J ^a   Martin, J ^b   Stribbling, S M ^b   Cushen, N ^a   O'Malley, D ^a   Begent, R H J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYPEPTIDASE G2; CARCINOEMBRYONIC ANTIBODY; CISPLATIN; FLUOROURACIL; FOLINIC ACID; MITOMYCIN C; N [4 [(2 CHLOROETHYL)(2 MESYLOXYETHYL)AMINO]BENZOYL]GLUTAMIC ACID; PRODRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MALE; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; GAMMA-GLUTAMYL HYDROLASE; GLUTAMATES; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; NITROGEN MUSTARD COMPOUNDS; PRODRUGS; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 12944288238     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bagshawe, K. D., Springer, C. J., Searle, F., Antoniw, P., Sharma, S. K., Melton, R. G., and Sherwood, R. F. A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer, 58: 700-703, 1988.
2. Springer, C. J., Bagshawe, K. D., Sharma, S. K., Searle, F., Boden, J. A., Antoniw, P., Burke, P. J., Rogers, G. T., Sherwood, R. F., and Melton, R. G. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy with three novel compounds. Eur. J. Cancer, 27: 1361-1366, 1991.
3. Antoniw, P., Springer, C. J., Bagshawe, K. D., Searle, F., Melton, R. G., Rogers, G. T., Burke, P. J., and Sherwood, R. F. Disposition of the prodrug 4-(bis(2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice. Br. J. Cancer, 62: 909-914, 1990.
4. Eccles, S. A., Court, W. J., Box, G. A., Dean, C. J., Melton, R. G., and Springer, C. J. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. Cancer Res., 54: 5171-5177, 1994.
5. Harwood, J., Britton, D. W., Southall, P. J., Boxer, G. M., Rawlins, G., and Rogers, G. T. Mapping epitope characteristics on carcinoembryonic antigen. Br. J. Cancer, 54: 75-82, 1986.
6. Milenic, D. E., Estaban, J. N., and Colcher, D. Comparison of methods for the generation of immunoreactive fragments of a monoclonal antibody (B72.3) reactive with human carcinomas. J. Immunol. Methods, 120: 71-83, 1989.
7. Sherwood, R. F., Melton, R. G., Alwan, S. M., and Hughes, P. Purification and properties of carboxypeptidase G2 from pseudomonas Sp strain R.S. 16; use of a novel triazine dye affinity method. Eur. J. Biochem., 148: 447-453, 1985.
8. Duncan, R. J. S., Weston, P. D., and Wrigglesworth, R. A new reagent which may be used to introduce sulphudral groups into proteins and its use in the preparation of conjugates for immunoassay. Ann. Biochem., 132: 68-73, 1983.
9. Melton, R. G., Boyle, J. M., Rogers, G. T., Burke, P., Bagshawe, K. D., and Sherwood, R. F. Optimisation of small-scale coupling of A5B7 monoclonal antibody to carboxypeptidase G2. J. Immunol. Methods, 158: 49-56, 1993.
10. Adam, T. Radioiodination for therapy. Ann. Clin. Biochem., 26: 244-245, 1989.
11. Sharma, S. K., Bagshawe, K. D., Burke, P. J., Boden, R. W., and Rogers, G. T. Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model. Br. J. Cancer, 61: 659-662, 1990.
12. Mattes, M. J. Biodistribution of antibodies after intraperitoneal or intravenous injection and effect of carbohydrate modification. J. Natl. Cancer Inst., 79: 855-863, 1987.
13. Sharma, S. K., Bagshawe, K. D., Burke, P. J., Boden, J. A., Rogers, G. T., Springer, C. J., Melton, R. G., and Sherwood, R. F. Galactosy-lated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy. Cancer (Phila.), 73: 1114-1120, 1994.
14. Springer, C. J., Antoniw, P..,Bagshawe, K. D., Searle, F., Bisset, G. M., and Jarman, M. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J. Med. Chem., 33: 677-681, 1990.
15. Cancer Research Campaign Operation Manual for control of production, preclinical toxicology and Phase I trials of anti-tumor antibodies and drug antibody conjugates. Br. J. Cancer, 54: 557-568, 1986.
16. Hughes, P., Lowe, C. R., and Sherwood, R. F. Metal ion-promoted binding of proteins to immobilized triazine dye affinity adsorbants. Biochim. Biophys. Acta, 700: 90-100, 1982.
17. McCulloch, J. L., Chabner, B. A., and Bertino, J. R. Purification and properties of carboxypeptidase Gl. J. Biol. Chem., 246: 7207-7213, 1971.
18. Green, A. J., Dewhurst, S. E., Begent, R. H., Bagshawe, K. D., and Riggs, S. J. Accurate quantification of 131I distribution by gamma camera imaging. Eur. J. Nucl. Med., 16: 361-365, 1990.
19. Sharma, S. K., Bagshawe, K. D., Melton, R. G., and Sherwood, R. F. Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial. Cell Biophys., 21: 109-120, 1992.
20. Springer, C. J., Poon, G. K., Sharma, S. K., and Bagshawe, K. D. Identification of prodrug, active drug, and metabolites in an ADEPT clinical study. Cell Biophys., 22: 9-26, 1993.
21. Martin, J., Stribbling, S. M., Poon, G. K., Begent, R. H. J., Napier, M. P., Sharma, S. K., and Springer, C. J. Antibody directed enzyme prodrug therapy (ADEPT): pharmacokinetics and plasma levels of prodrug and drug in a Phase I clinical trial. Cancer Chemother. Pharmacol., 40: 189-201, 1997.
22. Stribbling, S. M., Martin, J., Pedley, R. B., Boden, J. A., Sharma, S. K., and Springer, C. J. Biodistribution of an antibody-enzyme conjugate for ADEPT in nude mice bearing a human colon adenocarcinoma xenograft. Cancer Chemother. Pharmacol., 40: 277-284, 1997.
23. National Cancer Institute Common Toxicity Criteria. Bethesda, MD: National Cancer Institute, Division of Cancer Treatment, 1988.
24. Boxer, G. M., Abassi, A. M., Pedley, R. B., and Begent, R. H. J. Localisation of monoclonal antibodies reacting with different epitopes on carcinoembryonic antigen (CEA): implications for targeted therapy. Br. J. Cancer. 69: 307-314, 1994.
25. Springer, C. J., Antoniw, P., Bagshawe, K. D., and Wilman, D. E. V. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethylbenzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). Anti-Cancer Drug Design, 6: 467-479, 1991.
26. Bagshawe, K. D., Sharma, S. K., Springer, C. J., and Antoniw, P. Antibody directed enzyme prodrug therapy: a pilot scale clinical trial. Tumour Targeting, 7: 17-30, 1995.
27. Springer, C. J., Dowell, R., Burke, P. J., Hadley, E., Davis, D. H., Blakey, D. C., Melton, R. G., and Niculescu-Duvaz, I. Optimisation of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed prodrug therapy (ADEPT). J. Med. Chem., 38: 5051-5065, 1995.
28. Blakey, D. C., Burke, P. J., Davies, D. H., Dowell, R. I., East, S. J., Eckersley, K. P., Fitton, J. E., McDaid, J., Melton, R. G., Niculescu-Duvaz, I. A., Pinder, P. E., Sharma, S. K., Wright, A. F., and Springer, C. J. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumour xenografts. Cancer Res., 56: 3287-3292, 1996.
29. Korst, D. R., Johnson, F. D., Frenkel, E. P., and Challener, W. L. Preliminary evaluation of the effect of cyclophosphamide on the course of human neoplasms. Cancer Chemother. Rep., 7: 1-12, 1960.
30. Ledermann, J. A., Begent, R. H. J., Massof, C., Kelly, A. M., Adam, T., and Bagshawe, K. D. A Phase I study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin A to suppress the immune response. Int. J. Cancer, 47: 659-664, 1991.
31. Bagshawe, K. D., and Sharma, S. K. Cyclosporine delays host immune response to antibody enzyme conjugate in ADEPT. Transplantation Proceedings. 28: 3156-3158, .
32. Deierhoi, M. H., Kauffman, R. S., Hudson, S. L., Barber, W. H., Curtis, J. J., Julian, B. A., Gaston, R. S., Laskow, D. A., and Diethelm, A. G. Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center. Ann. Surg., 217: 476-484, 1993.
33. Dhingra, K., Fritsche, H.. Murray, J. L., LoBuglio, A. F., Khazaeli, M. B., Kelley, S., Tepper, M. A., Grasela, D. Buzdar, A., and Valero, O. Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res., 55: 3060-3067, 1995.